Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier.
暂无分享,去创建一个
Mauro Ferrari | Milos Kojic | Arturas Ziemys | Yuki Saito | Kenji Yokoi | Miljan Milosevic | Tomonori Tanei | M. Ferrari | D. Chan | A. Ziemys | M. Kojic | R. Matsunami | T. Tanei | K. Yokoi | Yuki Saito | Diana Chan | David Engler | Rise Matsunami | M. Milošević | David Engler
[1] A Ziemys,et al. A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure. , 2014, Computer methods in applied mechanics and engineering.
[2] P. Uster,et al. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. , 1997, British Journal of Cancer.
[3] R. Zhou,et al. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. , 2002, Cancer research.
[4] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[5] I. Rubinstein,et al. Role of nanotechnology in targeted drug delivery and imaging: a concise review. , 2005, Nanomedicine : nanotechnology, biology, and medicine.
[6] A P Pathak,et al. MR‐derived cerebral blood volume maps: Issues regarding histological validation and assessment of tumor angiogenesis , 2001, Magnetic resonance in medicine.
[7] Michael D. Abràmoff,et al. Image processing with ImageJ , 2004 .
[8] Mauro Ferrari,et al. Nanogeometry: beyond drug delivery. , 2008, Nature nanotechnology.
[9] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[10] Mauro Ferrari,et al. Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics , 2016, Drug delivery.
[11] G. Keating,et al. Pegylated Liposomal Doxorubicin , 2011, Drugs.
[12] C. Presant,et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.
[13] C. Presant,et al. Tumor‐based pharmacokinetics has greater significance for anticancer drugs than does blood‐based pharmacokinetics , 2004, Clinical pharmacology and therapeutics.
[14] N. Rapoport,et al. Intracellular distribution and intracellular dynamics of a spin-labeled analogue of doxorubicin fluorescence and EPR spectroscopy. , 1998, Journal of pharmaceutical sciences.
[15] D. Crothers,et al. Site selectivity of daunomycin. , 1994, Biochemistry.
[16] J. Carlsson,et al. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids , 2004, Cancer Chemotherapy and Pharmacology.
[17] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[18] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[19] N. Kojic,et al. Transport in biological systems , 2011 .
[20] Sanford M. Simon,et al. Intracellular pH and the control of multidrug resistance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[21] P. Low,et al. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.
[22] C. Davies,et al. The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules. , 2008, Anticancer research.
[23] Robert Langer,et al. Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.
[24] A. Ziemys,et al. The role of payload hydrophobicity in nanotherapeutic pharmacokinetics. , 2014, Journal of pharmaceutical sciences.
[25] Mauro Ferrari,et al. Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method , 2011, J. Comput. Phys..
[26] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[27] R. Rosenfeld,et al. Deciphering the fluorescence signature of daunomycin and doxorubicin. , 1998, Biophysical chemistry.
[28] Mauro Ferrari,et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. , 2014, Cancer letters.
[29] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[30] S. Wise. Nanocarriers as an emerging platform for cancer therapy , 2007 .
[31] M. Ferrari,et al. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. , 2013, Cancer letters.
[32] H. Derendorf,et al. Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue , 2004, Antimicrobial Agents and Chemotherapy.
[33] Mauro Ferrari,et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.
[34] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[36] J. Mcvie. The role of pharmacokinetics in (combination) chemotherapy , 1984, Cancer.
[37] C. Ardiet,et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. , 1997, Cancer treatment reviews.